Evidence map›Paper›PMID 38430455›Full record

ArticleRheumatology and therapy2024

Neutrophilic Activity Biomarkers (Plasma Neutrophil Extracellular Traps and Calprotectin) in Established Patients with Rheumatoid Arthritis Receiving Biological or JAK Inhibitors: A Clinical and Ultrasonographic Study.

Beatriz Frade-Sosa, Andrés Ponce, Estíbaliz Ruiz-Ortiz, Noemí De Moner, María J Gómara, Ana Belén Azuaga, Juan C Sarmiento-Monroy, Rosa Morlà, Virginia Ruiz-Esquide, Laura Macías and 10 more

Open access · goldAbstract read
In one paragraph

Article in Rheumatology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Beatriz Frade-SosaDepartment of Rheumatology, Hospital Clinic of Barcelona, Barcelona, IDIBAPS, Carrer Villarroel 170, 08170, Barcelona, Spain.ORCID http://orcid.org/0000-0002-5867-8434
Andrés PonceDepartment of Rheumatology, Hospital Clinic of Barcelona, Barcelona, IDIBAPS, Carrer Villarroel 170, 08170, Barcelona, Spain.ORCID http://orcid.org/0000-0003-3068-5752
Estíbaliz Ruiz-OrtizDepartment of Immunology-CDB, Hospital Clinic of Barcelona, Barcelona, Barcelona, Spain.
Noemí De MonerDepartment of Immunology-CDB, Hospital Clinic of Barcelona, Barcelona, Barcelona, Spain.
María J GómaraUnit of Synthesis and Biomedical Applications of Peptides, Institute for Advanced Chemistry of Catalonia. Consejo Superior de Investigaciones Científicas (IQAC-CSIC), Barcelona, Spain.
Ana Belén AzuagaDepartment of Rheumatology, Hospital Clinic of Barcelona, Barcelona, IDIBAPS, Carrer Villarroel 170, 08170, Barcelona, Spain.
Juan C Sarmiento-MonroyDepartment of Rheumatology, Hospital Clinic of Barcelona, Barcelona, IDIBAPS, Carrer Villarroel 170, 08170, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8426-7268
Rosa MorlàDepartment of Rheumatology, Hospital Clinic of Barcelona, Barcelona, IDIBAPS, Carrer Villarroel 170, 08170, Barcelona, Spain.ORCID http://orcid.org/0000-0002-2892-6142
Virginia Ruiz-EsquideDepartment of Rheumatology, Hospital Clinic of Barcelona, Barcelona, IDIBAPS, Carrer Villarroel 170, 08170, Barcelona, Spain.ORCID http://orcid.org/0000-0002-2657-6601
Laura MacíasBiochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8314-3087
Nuria SapenaDepartment of Rheumatology, Hospital Clinic of Barcelona, Barcelona, IDIBAPS, Carrer Villarroel 170, 08170, Barcelona, Spain.
Lola TobalinaDepartment of Rheumatology, Hospital Clinic of Barcelona, Barcelona, IDIBAPS, Carrer Villarroel 170, 08170, Barcelona, Spain.
Julio RamirezDepartment of Rheumatology, Hospital Clinic of Barcelona, Barcelona, IDIBAPS, Carrer Villarroel 170, 08170, Barcelona, Spain.
Juan D CañeteDepartment of Rheumatology, Hospital Clinic of Barcelona, Barcelona, IDIBAPS, Carrer Villarroel 170, 08170, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2606-0573
Jordi YagueDepartment of Immunology-CDB, Hospital Clinic of Barcelona, Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0002-1935-4488
Josep M AugeBiochemistry and Molecular Genetics Department, Hospital Clinic of Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0001-6383-7308
José A Gomez-PuertaDepartment of Rheumatology, Hospital Clinic of Barcelona, Barcelona, IDIBAPS, Carrer Villarroel 170, 08170, Barcelona, Spain.ORCID http://orcid.org/0000-0001-8177-702X
Odette ViñasDepartment of Immunology-CDB, Hospital Clinic of Barcelona, Barcelona, Barcelona, Spain.ORCID http://orcid.org/0000-0001-8488-9975
Isabel HaroUnit of Synthesis and Biomedical Applications of Peptides, Institute for Advanced Chemistry of Catalonia. Consejo Superior de Investigaciones Científicas (IQAC-CSIC), Barcelona, Spain.ORCID http://orcid.org/0000-0001-8677-2340
Raimon SanmartiDepartment of Rheumatology, Hospital Clinic of Barcelona, Barcelona, IDIBAPS, Carrer Villarroel 170, 08170, Barcelona, Spain. sanmarti@clinic.cat.ORCID http://orcid.org/0000-0002-8864-3806
Hospital Clínic de Barcelona · ESConsejo Superior de Investigaciones Científicas · ES

Funding

Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España PID2021-122216OB-I00
6 · The paper itself

Abstract

introductionThis study assesses the accuracy of neutrophil activation markers, including neutrophil extracellular traps (NETs) and calprotectin, as biomarkers of disease activity in patients with established rheumatoid arthritis (RA). We also analyse the relationship between NETs and various types of therapies as well as their association with autoimmunity.

methodsObservational cross-sectional study of patients with RA receiving treatment with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (JAK-inhibitors) for at least 3 months. Plasma calprotectin levels were measured using an enzyme-linked immunosorbent assay test kit and NETs by measuring their remnants in plasma (neutrophil elastase-DNA and histone-DNA complexes). We also assessed clinical disease activity, joint ultrasound findings and autoantibody status [reumatoid factor (RF), anti-citrullinated peptide/protein antibodies (ACPAs) and anti-carbamylated protein (anti-CarP)]. Associations between neutrophilic biomarkers and clinical or ultrasound scores were sought using correlation analysis. The discriminatory capacity of both neutrophilic biomarkers to detect ultrasound synovitis was analysed through receiver-operating characteristic (ROC) curves.

resultsOne hundred fourteen patients were included. Two control groups were included to compare NET levels. The active control group consisted of 15 patients. The second control group consisted of 30 healthy subjects. Plasma NET levels did not correlate with clinical disease status, regardless of the clinic index analysed or the biological therapy administered. No significant correlation was observed between NET remnants and ultrasound synovitis. There was no correlation between plasma NET and autoantibodies. In contrast, plasma calprotectin positively correlated with clinical parameters (swollen joint count [SJC] rho = 0.49; P < 0.001, Clinical Disease Activity Index [CDAI] rho = 0.30; P < 0.001) and ultrasound parameters (rho > 0.50; P < 0.001). Notably, this correlation was stronger than that observed with acute phase reactants.

conclusionWhile NET formation induced by neutrophils may play a role in RA pathogenesis, our study raises questions about the utility of NET remnants in peripheral circulation as a biomarker for inflammatory activity. In contrast, this study strongly supports the usefulness of calprotectin as a biomarker of inflammatory activity in patients with RA.

Indexed as

AutoimmunityCalprotectinJoint ultrasoundNETsRheumatoid arthritis

Identifiers

PMID38430455
PMCPMC11111434
OpenAlexW4392348215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.